BioCentury
ARTICLE | Clinical News

KB001-A: Phase II started

January 21, 2013 8:00 AM UTC

KaloBios began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 10 mg/kg IV KB001-A given up to 5 times over 16 weeks in about 180 patients. KB001-A differs from precursor molecule ...